Autologous transplant in multiple myeloma with an augmented conditioning protocol.

about

How we manage autologous stem cell transplantation for patients with multiple myeloma

P2860

Q34019581-75C7BE83-8903-42D1-9414-5FF535D52621

P2860

Autologous transplant in multiple myeloma with an augmented conditioning protocol.

Item

http://www.wikidata.org/entity/Q44687339

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Autologous transplant in multiple myeloma with an augmented conditioning protocol.

@en

Autologous transplant in multiple myeloma with an augmented conditioning protocol.

@nl

type

Item

label

Autologous transplant in multiple myeloma with an augmented conditioning protocol.

@en

Autologous transplant in multiple myeloma with an augmented conditioning protocol.

@nl

prefLabel

Autologous transplant in multiple myeloma with an augmented conditioning protocol.

@en

Autologous transplant in multiple myeloma with an augmented conditioning protocol.

@nl

P1476

Autologous transplant in multiple myeloma with an augmented conditioning protocol.

@en

P2093

Ali Abdul-Hai

http://www.w3.org/2001/XMLSchema#string

Badran Abu Zaid

http://www.w3.org/2001/XMLSchema#string

Igor B Resnick

http://www.w3.org/2001/XMLSchema#string

Lillian Dray

http://www.w3.org/2001/XMLSchema#string

Michael Y Shapira

http://www.w3.org/2001/XMLSchema#string

Panagiotis D Tsirigotis

http://www.w3.org/2001/XMLSchema#string

Reuven Or

http://www.w3.org/2001/XMLSchema#string

Simcha Samuel

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.

International uniform response criteria for multiple myeloma.

Autologous hematopoietic stem-cell transplantation for multiple myeloma.

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

New developments in conditioning regimens before auto-SCT in multiple myeloma.

Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.

P304

2480-2484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2013.782608

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Itamar Grotto

P577

2013-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23469964

http://www.w3.org/2001/XMLSchema#string

Autologous transplant in multiple myeloma with an augmented conditioning protocol.

about

P2860

P2860

Autologous transplant in multiple myeloma with an augmented conditioning protocol.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698